Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroscience Bulletin
Published in: Neuroscience Bulletin 4/2019

01-08-2019 | Cytokines | Review

The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application

Authors: Zhiang Niu, Lu Yang, Xiaohui Wu, Yuncheng Zhu, Jun Chen, Yiru Fang

Published in: Neuroscience Bulletin | Issue 4/2019

Login to get access

Abstract

Neuroimmune system may be involved in the pathological process of bipolar disorder (BD), but the essential association is not fully understood. Accumulating evidence has shown that BD involves the activation of immune cells and the release of inflammatory substances in the central nerve system (CNS). Meanwhile, neuroimmune responses also interact with other hypothesis of the etiology of BD that are widely recognized, such as neurotransmitter systems, neuroendocrine systems, neurotrophic factors, and oxidative stress. Simultaneously, related genes and immune changes in peripheral blood vary with it. Overall, neuroimmunity may play an important role in the pathogenesis of BD, and the inflammatory cytokines, especially interleukin-6 and tumor necrosis factor-alpha, have potential value for the clinical diagnosis and prognosis of BD, as well as predicting the therapeutic effects of drugs. Large-scale studies are needed to extend the evidence on neuroimmunity in BD, and to examine its clinical value for applications such as early prediction and treatment.
Literature
1.
2.
Panaro MA, Aloisi A, Nicolardi G, Lofrumento DD, Nuccio FD, Pesa VL, et al. Radio electric asymmetric conveyer technology modulates neuroinflammation in a mouse model of neurodegeneration. Neurosci Bull 2018, 34: 270–282.CrossRefPubMed
3.
Rosenblat JD, Mcintyre RS. Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. Brain Sciences 2017, 7: 144.CrossRefPubMedCentral
4.
O’Callaghan JP, Sriram K, Miller DB. Defining “neuroinflammation”. Ann N Y Acad Sci 2008,1139: 318–330.CrossRefPubMed
5.
Pinto JV, Passos IC, Librenza-Garcia D, Marcon G, Schneider MA, Conte JH, et al. Neuron-glia interaction as a possible pathophysiological mechanism of bipolar disorder. Curr Neuropharmacol 2018, 16: 519–532.CrossRefPubMedPubMedCentral
6.
7.
Ascoli BM, Gea LP, Colombo R, Barbe-Tuana FM, Kapczinski F, Rosa AR. The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets. Aust N Z J Psychiatry 2016, 50: 618–630.CrossRefPubMed
8.
Franco R, Fernandez-Suarez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 2015, 131: 65–86.CrossRefPubMed
9.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9: 46–56.CrossRefPubMedPubMedCentral
10.
Nakagawa Y, Chiba K. Diversity and plasticity of microglial cells in psychiatric and neurological disorders. Pharmacol Ther 2015, 154: 21–35.CrossRefPubMed
11.
12.
Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010, 15: 384–392.CrossRefPubMed
13.
Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 2015, 40: 250–258.CrossRefPubMedPubMedCentral
14.
Colombo E, Farina C. Astrocytes: Key Regulators of Neuroinflammation. Trends in Immunology 2016, 37: 608–620.CrossRefPubMed
15.
Drogemuller K, Helmuth U, Brunn A, Sakowicz-Burkiewicz M, Gutmann DH, Mueller W, et al. Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J Immunol 2008, 181: 2683–2693.CrossRefPubMed
16.
Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8: 247–256.CrossRefPubMed
17.
Papa M, De LC, Petta F, Alberghina L, Cirillo G. Astrocyte–neuron interplay in maladaptive plasticity. Neurosci Biobehav Rev 2014, 42: 35–54.CrossRefPubMed
18.
19.
20.
Domingues HS, Portugal CC, Socodato R, Relvas JB. Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol 2016, 4: 71. doi: 10.3389/fcell.2016.00071.CrossRefPubMedPubMedCentral
21.
Toker L, Mancarci BO, Tripathy S, Pavlidis P. Transcriptomic evidence for alterations in astrocytes and parvalbumin interneurons in subjects with bipolar disorder and schizophrenia. Biol Psychiatry 2018, 84: 787–796.CrossRefPubMedPubMedCentral
22.
Tomasz G, Schroeter ML, Wiebke L, Hans-Gert B, Henrik D, Kolja S, et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. Journal of Psychiatric Research 2013, 47: 1694–1699.CrossRef
23.
Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry 2006, 40: 217–224.PubMed
24.
da Rosa MI, Simon C, Grande AJ, Barichello T, Oses JP, Quevedo J. Serum S100B in manic bipolar disorder patients: Systematic review and meta-analysis. J Affect Disord 2016, 206: 210–215.CrossRefPubMed
25.
26.
Poletti S, De WH, Mazza E, Wijkhuijs AJ, Locatelli C, Aggio V, et al. Th17 cells correlate positively to the structural and functional integrity of the brain in bipolar depression and healthy controls. Brain Behav Immun 2017, 61: 317–325.CrossRefPubMed
27.
Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003, 100: 13632–13637.CrossRefPubMedPubMedCentral
28.
Isgren A, Jakobsson J, Palsson E, Ekman CJ, Johansson AG, Sellgren C, et al. Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav Immun 2015, 43: 198–204.CrossRefPubMed
29.
Isgren A, Sellgren C, Ekman CJ, Holménlarsson J, Blennow K, Zetterberg H, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: relation to prospective clinical outcomes. Brain Behav Immun 2017, 65: 195–201.CrossRefPubMed
30.
Wang AK, Miller BJ. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. Schizophr Bull 2018, 44: 75–83.CrossRefPubMed
31.
Munkholm K, Jacoby AS, Lenskjold T, Bruunsgaard H, Vinberg M, Kessing LV. Leukocytes in peripheral blood in patients with bipolar disorder–trait and state alterations and association with levels of cytokines and C-reactive protein. Psychiatry Res 2018, 261: 383–390.CrossRefPubMed
32.
Wu W, Zheng YL, Tian LP, Lai JB, Hu CC, Zhang P, et al. Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study. Scientific Reports 2017, 7: 40530.CrossRefPubMedPubMedCentral
33.
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013, 74: 15–25.CrossRefPubMed
34.
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016, 21: 1696–1709.CrossRefPubMedPubMedCentral
35.
Benedetti F, Mazza E, Poletti S, Bollettini I, Locatelli C, Colombo C, et al. Inflammatory cytokines influence measures of white matter integrity in bipolar disorder. Neurol Psychiatry Brain Res, 2016: 1–2.
36.
Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology 2017, 42: 193–215.CrossRefPubMed
37.
Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999, 88: 823–836.CrossRefPubMed
38.
Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009, 65: 296–303.CrossRefPubMed
39.
40.
Arnone D, Saraykar S, Salem H, Teixeira AL, Dantzer R, Selvaraj S. Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies. Neurosci Biobehav Rev 2018, 92: 477–485.CrossRefPubMedPubMedCentral
41.
Mukherjee D, Krishnamurthy VB, Millett CE, Reider A, Can A, Groer M, et al. Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. Bipolar Disord 2018, 20: 27–34.CrossRefPubMed
42.
Hsu JW, Lirng JF, Wang SJ, Lin CL, Yang KC, Liao MH, et al. Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study. Bipolar Disord 2014, 16: 241–248.CrossRefPubMed
43.
Chou YH, Hsieh WC, Chen LC, Lirng JF, Wang SJ. Association between the serotonin transporter and cytokines: Implications for the pathophysiology of bipolar disorder. J Affect Disord 2016, 191: 29–35.CrossRefPubMed
44.
McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87: 873–904.CrossRefPubMed
45.
Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, et al. MECHANISMS IN ENDOCRINOLOGY: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 2015, 173: R1–14.CrossRefPubMed
46.
Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 2001, 15: 361–373.
47.
Moisés E Bauer JCMM, Luz C The role of stress factors during aging of the immune system. Ann N Y Acad Sci, 2009, 1153: 139–152.CrossRef
48.
Bauer ME, Wieck A, Petersen LE, Baptista TS. Neuroendocrine and viral correlates of premature immunosenescence. Ann N Y Acad Sci 2015, 1351: 11–21.CrossRefPubMed
49.
Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003, 9: 3–24.PubMed
50.
Young AH. The Effects of HPA Axis Function on Cognition and Its Implications for the Pathophysiology of Bipolar Disorder. Harv Rev Psychiatry 2014, 22: 331–333.CrossRefPubMed
51.
Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015, 300: 141–154.CrossRefPubMed
52.
Spijker AT, Van Rossum EFC. Glucocorticoid Sensitivity in Mood Disorders. Neuroendocrinology 2012, 95: 179–186.CrossRefPubMed
53.
54.
Belvederi MM, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology 2016, 63: 327–342.CrossRef
55.
Valvassori SS, Resende WR, Dal-Pont G, Sangaletti-Pereira H, Gava FF, Peterle BR, et al. Lithium ameliorates sleep deprivation-induced mania-like behavior, hypothalamic-pituitary-adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine concentrations in the brain and serum of mice. Bipolar Disord 2017, 19: 246–258.CrossRefPubMed
56.
Wu R, Fan J, Zhao J, Calabrese JR, Gao K. The relationship between neurotrophins and bipolar disorder. Expert Rev Neurother 2014, 14: 51–65.CrossRefPubMed
57.
Jacoby AS, Munkholm K, Vinberg M, Pedersen BK, Kessing LV. Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder - Results from a prospective study. J Affect Disord 2016, 197: 167–174.CrossRefPubMed
58.
van den Ameele S, Coppens V, Schuermans J, De Boer P, Timmers M, Fransen E, et al. Neurotrophic and inflammatory markers in bipolar disorder: A prospective study. Psychoneuroendocrinology 2017, 84: 143–150.CrossRefPubMed
59.
Wang TY, Lee SY, Chen SL, Chang YH, Wang LJ, Chen PS, et al. Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder. Sci Rep 2016, 6: 27431.CrossRefPubMedPubMedCentral
60.
Hatch JK, Scola G, Olowoyeye O, Collins JE, Andreazza AC, Moody A, et al. Inflammatory Markers and Brain-Derived Neurotrophic Factor as Potential Bridges Linking Bipolar Disorder and Cardiovascular Risk Among Adolescents. J Clin Psychiatry 2017, 78: e286–e293.CrossRefPubMed
61.
Nunes SO, Lg PDM, Mr PDC, Barbosa DS, Vargas HO, Berk M, et al. Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord 2015, 172: 55–62.CrossRefPubMed
62.
Lgp DM, Sov N, Anderson G, Vargas HO, Barbosa DS, Galecki P, et al. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2017, 78: 34–50.CrossRef
63.
Vasconcelos-Moreno MP, Fries GR, Gubert C, Dos Santos BT, Fijtman A, Sartori J, et al. Telomere length, oxidative stress, inflammation and BDNF levels in siblings of patients with bipolar disorder: implications for accelerated cellular aging. Int J Neuropsychopharmacol 2017, 20: 445–454.CrossRefPubMedPubMedCentral
64.
Mondin TC, Cardoso TDA, Moreira FP, Wiener C, Oses JP, Souza LDDM, et al. Circadian preferences, oxidative stress and inflammatory cytokines in bipolar disorder: A community study. J Neuroimmunol 2016, 301: 23–29.CrossRefPubMed
65.
Ozdemircan A, Dasdemir S, Kucukali CI, Bireller ES, Ozturk H, Cakmakoglu B. COX-2 gene variants in bipolar disorder-I. Psychiatr Danub 2015, 27: 385–389.PubMed
66.
Rafiei A, Hosseini SH, Taheri M, Hosseni-khah Z, Hajilooi M, Mazaheri Z. Influence of IL-1RN intron 2 variable number of tandem repeats (VNTR) polymorphism on bipolar disorder. Neuropsychobiology 2013, 67: 116–121.CrossRefPubMed
67.
Yoon HK, Kim YK. The T allele of the interferon-gamma +874A/T polymorphism is associated with bipolar disorder. Nord J Psychiatry 2012, 66: 14–18.CrossRefPubMed
68.
Altamura AC, Mundo E, Cattaneo E, Pozzoli S, Dell’osso B, Gennarelli M, et al. The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 2010, 17: 126–131.CrossRefPubMed
69.
Clerici M, Arosio B, Mundo E, Cattaneo E, Pozzoli S, Dell’osso B, et al. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr 2009, 14: 419–425.CrossRefPubMed
70.
Papiol S, Rosa A, Gutierrez B, Martin B, Salgado P, Catalan R, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet 2004, 41: 219–223.CrossRefPubMedPubMedCentral
71.
Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF, 3rd, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014, 29: 635–644.CrossRefPubMed
72.
Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry 2016, 21: 1090–1098.CrossRefPubMed
73.
Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, De HW, Wijkhuijs A, et al. Higher baseline proinflammatory cytokines mark poor antidepressant response in bipolar disorder. J Clin Psychiatry 2017, 78: e986–e993.CrossRefPubMed
74.
Calati R, Crisafulli C, Balestri M, Serretti A, Spina E, Calabro M, et al. Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2013, 44: 271–278.CrossRefPubMed
75.
Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, et al. Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiatry 2018, 75: 65–74.PubMed
76.
77.
Goldstein BI, Kemp DE, Soczynska JK, Mcintyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70: 1078–1090.CrossRefPubMed
78.
Pandey GN. Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain. Mod Trends Pharmacopsychiatry 2017, 31: 79–95.CrossRefPubMed
79.
Ghafelehbashi H, Pahlevan MK, Kular L, Moghbelinejad S, Ghafelehbashi SH. Decreased expression of IFNG-AS1, IFNG and IL-1B inflammatory genes in medicated Schizophrenia and Bipolar patients. Scand J Immunol 2017, 86: 479–485.CrossRefPubMed
80.
Akcan U, Karabulut S, C İK, S Ç, Tüzün E. Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels. Acta Neuropsychiatr 2018, 30: 70–78.
81.
Vogels RJ, Koenders MA, van Rossum EF, Spijker AT, Drexhage HA. T cell deficits and overexpression of hepatocyte growth factor in anti-inflammatory circulating monocytes of middle-aged patients with bipolar disorder characterized by a high prevalence of the metabolic syndrome. Front Psychiatry 2017, 8: 34.CrossRefPubMedPubMedCentral
82.
Ferrari P, Parisi MM, Colombo R, Becker M, Fries G, Ascoli BM, et al. Depression and mania induce pro-inflammatory activation of macrophages following application of serum from individuals with bipolar disorder. Clin Psychopharmacol Neurosci 2018, 16: 103–108.CrossRefPubMedPubMedCentral
83.
Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, et al. Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiatry 2017, 75: 65–74.PubMedCentral
84.
Hayes JF, Khandaker GM, Anderson J, Mackay D, Zammit S, Lewis G, et al. Childhood interleukin-6, C-reactive protein and atopic disorders as risk factors for hypomanic symptoms in young adulthood: a longitudinal birth cohort study. Psychol Med 2017, 47: 23–33.CrossRefPubMed
85.
Zeni-Graiff M, Rizzo LB, Mansur RB, Maurya PK, Sethi S, Cunha GR, et al. Peripheral immuno-inflammatory abnormalities in ultra-high risk of developing psychosis. Schizophrenia Res 2016, 176: 191–195.CrossRef
86.
Cheslack-Postava K, Cremers S, Bao Y, Shen L, Schaefer CA, Brown AS. Maternal serum cytokine levels and risk of bipolar disorder. Brain Behav Immun 2017, 63: 108–114.CrossRefPubMed
87.
Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R, et al. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res 2017, 84: 113–118.CrossRefPubMed
88.
van den Ameele S, van Diermen L, Staels W, Coppens V, Dumont G, Sabbe B, et al. The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review. J Affect Disord 2016, 203: 364–373.CrossRefPubMed
89.
Barbisan F, Azzolin VF, Teixeira CF, Mastella MH, Ribeiro EE, do Prado-Lima PAS, et al. Xanthine-catechin mixture enhances lithium-induced anti-inflammatory response in activated macrophages in vitro. Biomed Res Int 2017, 2017: 4151594.CrossRefPubMedPubMedCentral
90.
Valvassori SS, Resende WR, Dal-Pont G, Sangaletti-Pereira H, Gava FF, Peterle BR, et al. Lithium ameliorates sleep deprivation-induced mania-like behavior, hypothalamic-pituitary-adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine concentrations in the brain and serum of mice. Bipolar Disord 2017, 19: 246–258.CrossRefPubMed
91.
Benedetti F, Poletti S, Radaelli D, Locatelli C, Pirovano A, Lorenzi C, et al. Lithium and GSK-3beta promoter gene variants influence cortical gray matter volumes in bipolar disorder. Psychopharmacology (Berl) 2015, 232: 1325–1336.CrossRef
92.
Valvassori SS, Resende WR, Varela RB, Arent CO, Gava FF, Peterle BR, et al. The effects of histone deacetylase inhibition on the levels of cerebral cytokines in an animal model of mania induced by dextroamphetamine. Mol Neurobiol 2018, 55:1430-1439.CrossRefPubMed
93.
Leu SJ, Yang YY, Liu HC, Cheng CY, Wu YC, Huang MC, et al. Valproic acid and lithium meditate anti-inflammatory effects by differentially modulating dendritic cell differentiation and function. J Cell Physiol 2017, 232: 1176–1186.CrossRefPubMed
94.
Bortolasci CC, Spolding B, Callaly E, Martin S, Panizzutti B, Kidnapillai S, et al. Mechanisms underpinning the polypharmacy effects of medications in psychiatry. Int J Neuropsychopharmacol 2018.
95.
Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013, 30: 297–306.CrossRefPubMedPubMedCentral
96.
Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 2016, 18: 89–101.CrossRefPubMed
97.
Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry 2018, 8: 27.CrossRefPubMedPubMedCentral
98.
Soczynska JK, Kennedy SH, Alsuwaidan M, Mansur RB, Li M, Mcandrews MP, et al. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord 2017, 19: 198–213.CrossRefPubMed
99.
Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord 2015, 17: 606–614.CrossRefPubMed
100.
Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. J Affect Disord 2015, 188: 149–159.CrossRefPubMed
Metadata
Title
The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application
Authors
Zhiang Niu
Lu Yang
Xiaohui Wu
Yuncheng Zhu
Jun Chen
Yiru Fang
Publication date
01-08-2019
Publisher
Springer Singapore
Keyword
Cytokines
Published in
Neuroscience Bulletin / Issue 4/2019
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-019-00403-7

Other articles of this Issue 4/2019

Neuroscience Bulletin 4/2019 Go to the issue

Letter to the Editor

Association of Genetic Polymorphisms with Age at Onset in Han Chinese Patients with Bipolar Disorder

Original Article

Rac1 Modulates Excitatory Synaptic Transmission in Mouse Retinal Ganglion Cells

Correction

Correction to: Expression and Function of Zinc-α2-Glycoprotein

Original Article

Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

Letter to the Editor

Dynamic Alterations in Spontaneous Brain Activity in Mothers: A Resting-State Functional Magnetic Resonance Imaging Study

Original Article

Antidepressant-Like Action of Single Facial Injection of Botulinum Neurotoxin A is Associated with Augmented 5-HT Levels and BDNF/ERK/CREB Pathways in Mouse Brain